Johnson & Johnson (NYSE:JNJ) Holdings Lifted by Baker Ellis Asset Management LLC

Baker Ellis Asset Management LLC boosted its position in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 3.9% in the 1st quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 37,957 shares of the company’s stock after buying an additional 1,411 shares during the quarter. Johnson & Johnson accounts for approximately 1.2% of Baker Ellis Asset Management LLC’s investment portfolio, making the stock its 21st largest position. Baker Ellis Asset Management LLC’s holdings in Johnson & Johnson were worth $6,727,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of the company. Financial Advisory Service Inc. boosted its stake in Johnson & Johnson by 10.5% during the first quarter. Financial Advisory Service Inc. now owns 23,094 shares of the company’s stock valued at $4,093,000 after buying an additional 2,191 shares in the last quarter. Legacy Financial Advisors Inc. lifted its holdings in shares of Johnson & Johnson by 4.2% during the first quarter. Legacy Financial Advisors Inc. now owns 13,573 shares of the company’s stock valued at $2,406,000 after purchasing an additional 544 shares during the last quarter. Evolution Advisers Inc. lifted its holdings in shares of Johnson & Johnson by 212.8% during the first quarter. Evolution Advisers Inc. now owns 294 shares of the company’s stock valued at $52,000 after purchasing an additional 200 shares during the last quarter. AlphaCore Capital LLC lifted its holdings in shares of Johnson & Johnson by 287.6% during the first quarter. AlphaCore Capital LLC now owns 5,411 shares of the company’s stock valued at $959,000 after purchasing an additional 4,015 shares during the last quarter. Finally, Stephens Inc. AR lifted its holdings in shares of Johnson & Johnson by 2.7% during the first quarter. Stephens Inc. AR now owns 215,897 shares of the company’s stock valued at $38,263,000 after purchasing an additional 5,667 shares during the last quarter. Institutional investors own 68.78% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently commented on JNJ. The Goldman Sachs Group upped their target price on Johnson & Johnson from $163.00 to $181.00 and gave the company a “neutral” rating in a report on Tuesday, April 12th. UBS Group reduced their target price on Johnson & Johnson from $185.00 to $180.00 in a report on Thursday, July 21st. Citigroup reduced their target price on Johnson & Johnson from $205.00 to $201.00 in a report on Wednesday, July 20th. Morgan Stanley increased their price objective on Johnson & Johnson from $173.00 to $174.00 and gave the stock an “equal weight” rating in a research note on Friday, July 8th. Finally, SVB Leerink reduced their price objective on Johnson & Johnson from $200.00 to $194.00 in a research note on Wednesday, July 20th. Four analysts have rated the stock with a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $189.89.

Johnson & Johnson Stock Down 0.4 %

JNJ opened at $171.11 on Friday. Johnson & Johnson has a fifty-two week low of $155.72 and a fifty-two week high of $186.69. The business has a 50-day moving average of $175.21 and a 200-day moving average of $174.55. The company has a debt-to-equity ratio of 0.37, a current ratio of 1.42 and a quick ratio of 1.14. The company has a market capitalization of $449.88 billion, a PE ratio of 24.91, a price-to-earnings-growth ratio of 3.32 and a beta of 0.59.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, July 19th. The company reported $2.59 earnings per share for the quarter, topping analysts’ consensus estimates of $2.57 by $0.02. Johnson & Johnson had a return on equity of 36.14% and a net margin of 19.21%. The company had revenue of $24.02 billion during the quarter, compared to the consensus estimate of $23.85 billion. During the same period last year, the business earned $2.48 EPS. The business’s quarterly revenue was up 3.0% on a year-over-year basis. Equities research analysts forecast that Johnson & Johnson will post 10.05 EPS for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 6th. Stockholders of record on Tuesday, August 23rd will be issued a dividend of $1.13 per share. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.64%. The ex-dividend date of this dividend is Monday, August 22nd. Johnson & Johnson’s dividend payout ratio is 65.79%.

Insider Activity

In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CAO Robert J. Decker sold 8,462 shares of the stock in a transaction dated Thursday, May 26th. The stock was sold at an average price of $180.00, for a total transaction of $1,523,160.00. Following the transaction, the chief accounting officer now owns 15,473 shares of the company’s stock, valued at approximately $2,785,140. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Kathryn E. Wengel sold 40,000 shares of the firm’s stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the sale, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The disclosure for this sale can be found here. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Profile

(Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

Further Reading

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.